Spirecut
Muttenz · Founded 2020
About Spirecut
Long post-operative recovery creates a barrier for patients to access the care in routine surgeries. Over 2 million patients refrain from surgery because they cannot afford to be off-work. Spirecut's breakthrough incision-free surgery technology, enables patients to return to work next day. The technique is applicable to most common surgeries like Carpal Tunnel, Trigger Finger, Ganglion Cysts representing a patient group bigger than diabetes. Technique is particularly suitable for diabetic patients who often have these conditions and suffer from post-operative infection and wound healing issues. Spirecut's single-use instruments removes the need for a fully-equipped Operating Room and anesthetist, such that surgeries can be done even in remote areas without hospitals, enabling distributed care.
Company Facts
- Founded: 2020
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2024)
- Website: https://www.spirecut.com
- Phone: +41 26-505-18-38
Industries & Categories
Manufacturing, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/spirecut-60286 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.